Kristi Rosa | Authors

September 29, 2021

According to phase 1 data from the MagnetisMM-1 trial, elranatamab may be a good treatment option for patients with relapsed/refractory multiple myeloma.

September 18, 2021

In patients with persistent, recurrent, or metastatic cervical cancer the addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates.

September 18, 2021

In previously untreated patients with metastatic or unresectable melanoma, the addition of relatlimab to nivolumab prolonged benefit beyond initial treatment and first progression and reduced the risk of progression or death after the next line of systemic therapy vs nivolumab alone.

September 16, 2021

A 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression was seen with brigatinib compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

September 15, 2021

Durable responses in patients with low-grade upper tract urothelial carcinoma were seen with the mitomycin- containing reverse thermal gel UGN-101.

September 11, 2021

Overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177 may be impacted by Cancer and Leukemia Group B prognostic risk group and the receipt of subsequent FDA-approved life-prolonging therapies.